ArQule

ArQule, Inc. is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. The Company employs technologies, such as its ArQule Kinase Inhibitor Platform (AKIP) to design and develop drugs. The Company's product is ARQ 197, an orally administered inhibitor of the c-Met receptor tyrosine kinase. ARQ 197 is being evaluated as monotherapy and in combination therapy in a Phase II clinical development program that includes trials in Microphthalmia Transcription Factor (MiT) associated tumors, non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma and hepatocellular carcinoma (HCC). The Company has licensed commercial rights to ARQ 197 for human cancer indications to Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) in the United States, Europe, South America and the rest of the world, excluding Japan and certain other Asian countries, where it has licensed commercial rights to Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin).

Axsome Therapeutics

Constellation Pharmaceuticals Inc

DURECT

EverBank Financial

IVERIC bio Inc

Kodiak Sciences Inc

Provention Bio Inc

AVITA Medical Inc

Stage Stores

These Were the 10 Best Stocks of 2019

This cancer-drug developer received a buyout offer from a big pharmaceutical company.

Why Biotech Stock ArQule Soared 108% in December

Arrowhead Pharmaceuticals

Eidos Therapeutics Inc

Guardant Health Inc

Medpace Holdings

NeoGenomics

Nevro

Tenet Healthcare

Zoetis

Helping people stricken with illness can be richly rewarding in more ways than one.

These Were the 10 Best Healthcare Stocks of 2019

Merck

Merck's Latest $2.7-Billion Buy Of ArQule Brings About Precision Targeted And Diversified Approach To Cancer Therapy

Merck (MRK) offers to acquire ArQule for a deal value of $2.7 billion. The transaction will add ArQule's lead investigational candidate ARQ 531 to Merck's oncology portfolio.

Merck to Buy ArQule for $2.7B to Boost Cancer Portfolio

Drug giant Merck & Co. agreed Monday to acquire ArQule, a cancer-treating biopharmaceutical company, for $20 per share in cash for a total equity value of around $2.7 billion.

Shares of cancer-treatment company ArQule surge 100 percent on Merck acquisition

A $2.7 billion buyout offer is causing this biotech stock to take off.

Why ArQule Shares Are Skyrocketing Today

Thor Industries

XBiotech

Monday was a breakout day for a few biotech companies. Some made absolutely massive runs, practically doubling and then some.

Why These 3 Biotechs More Than Doubled on Monday

Spark Therapeutics

Roche Holding AG

Sanofi

Synthorx Inc

Week Begins with Biotech Mergers

Large-cap pharmaceutical companies are putting their assets to work in the biotech space, particularly in cancer treatment (oncology).

Merger Monday, Biotech Edition: MRK, SNY, ARQL, THOR & More

Merck (NYSE: MRK) will acquire ArQule, Inc. (NASDAQ: ARQL) for $20 per share in cash for an approximate total equity value of $2.7 billion.

ArQule To Be Acquired By Merck For $2.7B

Merck said on Monday it would buy cancer drug developer ArQule in a $2.7 billion all-cash deal, bolstering its oncology franchise with the smaller rival's lead drug that is being tested as a treatment for blood cancer.

Merck to buy cancer drug developer ArQule for $2.7 billion in cash

Merck & Co. Inc. MRK, +0.11% said Monday it has entered an agreement to acquire ArQule Inc.

Merck to acquire ArQule for $20 per share in cash or about $2.7 billion

Bristol-Myers

Eli Lilly

These companies have some important presentations scheduled for the last big oncology conference of the year.

3 Biotech Stocks With a Lot to Prove at ASH 2019

Adverum Biotechnologies

Here's how they could keep on rocketing higher.

3 Soaring Biotech Stocks to Watch in December

An update from an ongoing clinical trial appears to have disappointed investors, but that's not actually warranted by the data.

Here's Why ArQule Fell as Much as 28.3% Today

ArQule Moves Along With Registrational Mosaic Study

ArQule, Inc. (ARQL) CEO Paolo Pucci on Q3 2019 Results- Earnings Call Transcript

ArQule (ARQL) delivered earnings and revenue surprises of 0.00% and -82.67%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

ArQule (ARQL) Reports Q3 Loss, Lags Revenue Estimates

ArQule (ARQL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About ArQule (ARQL) Rating Upgrade to Buy

ARQL has outlicensed its lead drug after a proof of concept trial and will receive royalties and milestones.

ArQule: With Its Developing R&D Pipeline, We Are Looking For A Pullback

ArQule (ARQL) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

ArQule (ARQL) in Focus: Stock Moves 6.2% Higher

The pharma company has wowed investors with solid clinical data multiple times this year.

ArQule: Buy the Dip?

ArQule plunged 9% despite the absence of company-specific negative news.

ArQule: Still Has Room To Run In 2019

ArQule, Inc. (ARQL) CEO Paolo Pucci on Q2 2019 Results - Earnings Call Transcript

News for ArQule Stock (ARQL)